Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 7/20 | 0.70 |
| ▸ | MEN1 | O00255 | 6/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.70 |
| ▸ | HTT | P42858 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.62 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | NPC1 | O15118 | 6/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27093081 | 1.00 | LMNA (0.70) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL18824277 | 0.87 | DYRK1A (0.74) | LMNAMAPTMEN1KMT2APOLB | |
| SCHEMBL27093269 | 0.86 | HSD17B10 (0.71) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL27093078 | 0.86 | KDR (0.75) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL31206306 | 0.85 | MAPT (0.73) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL6225459 | 0.85 | MAPT (0.73) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL27093085 | 0.85 | HSD17B10 (0.72) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL21568341 | 0.84 | HSD17B10 (0.72) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL17287802 | 0.83 | CSNK1D (0.68) | LMNAMAPTMEN1KMT2AHTT | |
| SCHEMBL21568259 | 0.83 | LMNA (0.66) | LMNAMAPTMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199562-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-06-20 | — | — | US | claimed |
| EP-4322944-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Centre National de la Recherche Scientifique (FR) | 2024-02-21 | — | — | EP | claimed |
| WO-2022219123-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-20 | — | — | WO | claimed |
| US-20240199562-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Institut National de la Santé et de la Recherche Médicale (FR) | 2024-06-20 | — | — | US | disclosed |
| EP-4322944-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | Centre National de la Recherche Scientifique (FR) | 2024-02-21 | — | — | EP | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731985-B2 | Compositions and methods for treating cancer | HB THERAPEUTICS INC. (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2022219123-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-10-20 | — | — | WO | disclosed |
| WO-2019217509-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | HB THERAPEUTICS INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731985-B2 | Compositions and methods for treating cancer | VHL, TP53, NUDT1 | LMNA 2105/4885MAPT 1476/4885MEN1 977/4885 |
| US-20240199562-A1 | UREA DERIVATIVES FOR TREATING UVEAL MELANOMA | UACA, SLC14A1, MITF | LMNA 3486/4885MAPT 409/4885MEN1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.